Evolution of a Novel, Orally Bioavailable Series of PI3K delta Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.
Amour, A., Barton, N., Cooper, A.W., Inglis, G., Jamieson, C., Luscombe, C.N., Morrell, J., Peace, S., Perez, D., Rowland, P., Tame, C., Uddin, S., Vitulli, G., Wellaway, N.(2016) J Med Chem 59: 7239-7251
- PubMed: 27429068 
- DOI: https://doi.org/10.1021/acs.jmedchem.6b00799
- Primary Citation of Related Structures:  
5L72 - PubMed Abstract: 
A four-step process of high-quality modeling of existing data, deconstruction, identification of replacement cores, and an innovative synthetic regrowth strategy led to the rapid discovery of a novel oral series of PI3Kδ inhibitors with promising selectivity and excellent in vivo characteristics.
Organizational Affiliation: 
GlaxoSmithKline R&D , Gunnels Wood Road, Stevenage SG1 2NY, U.K.